Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: gg cox who wrote (11819)	1/4/2003 7:52:13 PM
From: axial	Read Replies (3) \| Respond to of 14101

Hi, gg - Well, not the ringing endorsement that we have from some other Pennsaid users, but "...I would certainly recommend Pennsaid for joint Pain relief" is good enough. I wonder whether he used it sparingly, and how much pain he is normally accustomed to. Some of the people I know who have OA find aspirin equivalent to putting a band-aid on an amputation. In any case, he won't be getting GI bleeding from Pennsaid. Still, it's good to see another positive report. Any way we slice-and-dice the figures, if Pennsaid captures 10% of the OA market (estimated at 20 million plus and growing) then that's 2 million, times however many times a year they re-order: let's say three times a year - that's 6 million bottles in a year. Times $30 CDN = $180 million, at 25% profit, $45 million per year. Assuming it takes a couple of years, and dilution grows to 60 million, that shows US earnings of $0.75 CDN, give it a P/E of 20, and you have a share price of $15 CDN. That excludes other earnings, of course. FDA approval should give us an upfront of around another $1/share, at least. WF10 - who knows? Pennsaid alone should put DMX solidly in the black - though it won't be immediate. None of this is meant to detract from Wolf's more detailed, and more reliable estimates. Regards, Jim